116 Views | 136 Downloads
Correspondence: sternsons@janelia.hhmi.org (S.M.S.)
Author contributions: Author contributions: C.M. performed ex vivo electrophysiology and SNr silencing behavioral experiments. P.L. developed and synthesized uPSEMs and performed dose response assays with C.M. M.R. made ion channel constructs. J.B., J.G., and M.M. performed PET imaging and radioligand displacement at PSAM4-GlyR and α7 nAChR. X.
H. and A.G. performed rhesus macaque experiments. R.Z. and J.B. performed in vivo calcium imaging. S.M.S. conceived the project, designed experiments, and wrote the paper with input from all the authors.
We thank Prof. Jon Lindstrom for providing stable cell lines expressing human α4β2 nAChR or α7 nAChR. Receptor counter-screening and associated Ki determinations were generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, Contract # HHSN-271–2013-00017-C (NIMH PDSP).
We are grateful for support from Janelia core facility staff; Sarah Lindo performed in utero electroporations.
Disclosures: S.M.S., C.J.M., and P.H.L. have pending patents on this technology and own stock in Redpin Therapeutics, LLC, which is a biotech company focusing on therapeutic applications of chemogenetics. S.M.S. is a cofounder and consultant for Redpin Therapeutics. M.M. is a cofounder and owns stock in Metis Laboratories, Inc.
S.M.S., C.M., P.L., and M.R. were funded by HHMI. X.H. and A.G. was supported by grant NIH ORIP OD P51-OD011132 to the Yerkes National Primate Research Center.
J.B. was supported by the Alfred P. Sloan Foundation, Klingenstein-Simons Foundation, NIH NINDS 1R01 NS109362–01, and Whitehall Foundation. M.M. is funded through NIDA IRP (ZIA000069).
© 2019 American Association for the Advancement of Science. All rights reserved.